Biologic agents in the treatment of inflammatory rheumatic diseases

Current Opinion in Rheumatology

Volumn 9, Issue 3, 1997, Pages 206-212

  Kalden, Joachim R ^a   Manger, Bernhard ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRHEUMATIC AGENT; CYTOKINE; IMMUNOGLOBULIN; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 4; MEMBRANE ANTIGEN; METHOTREXATE; OKT 4; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

AUTOIMMUNITY; DRUG MEGADOSE; DRUG THERAPY; ETIOLOGY; HUMAN; PRIORITY JOURNAL; REVIEW; RHEUMATIC DISEASE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, SURFACE; BIOLOGICAL PRODUCTS; CYTOKINES; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; INFLAMMATION MEDIATORS; INTERLEUKIN-1; RHEUMATIC DISEASES;

EID: 0030928196     PISSN: 10408711     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002281-199705000-00006     Document Type: Review

References (40)

1. Genain CP, Abel K, Belmar N, Villinger F, Rosenberg DP, Linington C, Raine CS, Hauser SL: Late complications of immune deviation therapy in a nonhuman primate. Science 1996, 274:2054-2057. Although the onset of experimental allergic encephalomyelitis was demonstrated to be delayed by treatment with myelin oligondendrocite glycoprotein, treated animals subsequently developed a hyperacute form of the disease.
2. Blanas E, Carbone FR, Allison J, Miller JFAP, Heath WR: Induction of autoimmune diabetes by oral administration of autoantigen. Science 1996, 274:1707-1709. In an animal model it was shown that the oral administration of autoantigenes could induce a cytotoxic T-lymphocyte response, which could lead to the onset of autoimmune diabetes.
3. Thompson RA, Lachmann PJ, Winchester RJ, eds: Intravenous immune globulin: mechanisms of action and model disease states. Clin Exp Immunol 1996, 104(suppl 1):1-97. A supplemental volume summarizing the proceedings of a symposium on immunoglobulin therapy in a variety of autoimmune diseases.
4. Kahaly GJ (ed): Immunoglobulins in autoimmunity: fundamentals and clinical applications. Clin Exp Rheumatol 1996, 14(suppl 15):S3-S119. A supplement volume summarizing the proceedings of a symposium on immunoglobulin therapy in a variety of autoimmune diseases.
5. Stohl W, Elliot JE: In vitro inhibition by intravenous immunoglobulin of human T cell-dependent B cell differentiation induced by staphylococcal superantigens. Clin Immunol Immunopathol 1996, 79:122-133.
6. Zouali M, Isenberg DA, Morrow WJW: Idiotype manipulation for autoimmune diseases: where are we going? Autoimmunity 1996, 24:55-63. Links between idiotypes and certain autoimmune diseases are discussed, including the possibility that autoimmune diseases could be managed by modulation with antibodies or peptides targeted to these structures.
7. Matteson EL, Shbeeb MI, McCarthy TG, Calamia KT, Mertz LE, Goronzy JJ: Pilot study of antithymocyte globulin in systemic sclerosis. Arthritis Rheum 1996, 39:1132-1137.
8. Kalden JR, Manger B: Biologic agents in the treatment of inflammatory rheumatic diseases. Curr Opin Rheumatol 1996, 8:195-200.
9. Moreland LW, Heck LW Jr, Koopman WJ, Saway PA, Adamson TC, Fronek Z, O'Connor RD, Morgan EE, Diveley JP, Richieri SP, et al.: Vβ17 T cell receptor peptide vaccination in rheumatoid arthritis: results of phase I dose escalation study. J Rheumatol 1996, 23:1353-1362. First report of a phase I open-vaccination trial using Vβ17 T-cell receptor peptides. Data on lymphocyte and clinical responses are presented.
10. Kroemer G, Hirsch F, Gonzalez-Garcia A, Martinez AC: Differential involvement of Th1 and Th2 cytokines in autoimmune diseases. Autoimmunity 1996, 24:25-33. The differential involvement of Th1 and Th2 cytokines in autoimmune diseases is discussed as a potential base for the development of therapeutic interventions by the recovery of a normal Th1 and Th2 balance.
11. Adorini L, Guery JC, Trembleau S: Manipulation of the Th1/Th2 cell balance: an approach to treat human autoimmune diseases? Autoimmunity 1996, 23:53-68. A good review paper on the implications of the Th1/Th2 concept for the pathogenesis and potential treatment of autoimmune diseases.
12. + T-cell depletion, no clinical efficacy was reported for anti-CD4 treatment in combination with methotrexate.
13. Panayi GS, Choy EHS, Conolly DJA, Regan T, Manna VK, Rapson N, Kingsley GH, Johnston JM: T cell hypothesis in rheumatoid arthritis tested by humanized non-depleting anti-CD4 monoclonal antibody (mAB) treatment I: suppression of disease activity and acute phase response [abstract]. Arthritis Rheum 1996, 39(suppl 9):243.
14. Choy EHS, Conollay DJA, Regan T, Mann VK, Rapson N, Kingles GH, Panavi GS, Johnston JM: T cell hypothesis in rheumatoid arthritis tested by humanized non-depleting anti-CD4 monoclonal antibody (mAB) treatment II: clinical activity is related to pharmacodynamic effects [abstract]. Arthritis Rheum 1996, 39(suppl 9):244.
15. Chu CQ, Londei M: Induction of Th2 cytokines and control of collagen-induced arthritis by nondepleting anti-CD4 Abs. J Immunol 1996, 157:2685-2689. Data are reported demonstrating that CIA nondepleting anti-CD4 monoclonal antibodies could be effective in inducing a shift from a Th1- to a Th2-like immune response.
16. + cells to a prevalence of activated memory subsets was demonstrated, reversing autoantibody production and increasing longevity in the B x SB model.
17. Weinblatt ME, Maddison PJ, Bulpitt KJ, Hazleman BL, Urowitz MB, Sturrock RD, Coblyn JS, Maier AL, Spreen WR, et al: CAMPATH-1H humanized monoclonal antibody, in refractory rheumatoid arthritis: an intravenous dose-escalation study. Arthritis Rheum 1995, 38:1589-1594. Treatment with the anti-CD52 antibody CAMPATH-1 H produces a profound immediate and sustained reduction of the peripheral lymphocyte count. Sixty-five percent of patients developed a clinical response without correlation to the biologic effect.
18. Oppenheimer-Marks N, Lipsky PE: Adhesion molecules as targets for the treatment of autoimmune diseases. Clin Immunol Immunopathol 1996, 79:203-210. Comprehensive review of adhesion molecules and their potential role as targets for the treatment of autoimmune diseases.
19. Halloran MM, Szekanecz Z, Barquin N, Haines GK, Koch AE: Cellular adhesion molecules in rat adjuvant arthritis. Arthritis Rheum 1996, 39:810-819.
20. Bullard DC, Hurley LA, Lorenzo I, Sly LM, Beaudet AL, Starte ND: Reduced susceptibility to collagen-induced arthritis in mice deficient in intercellular adhesion molecule-1. J Immunol 1996, 157:3153-3158.
21. Kavanaugh AF, Davis LS, Jain RI, Nichols LA, Morris SH, Lipsky PE: A phase I/II open label study of the safety and efficacy of an anti-ICAM-1 (intercellular adhesion molecule-1; CD54) monoclonal antibody in early rheumatoid arthritis. J Rheumatol 1996, 23:1338-1344. In a phase I and II open-label study with anti-ICAM-1 monoclonal antibody in early RA, seven of 10 patients had a marked or moderate response to a single course of therapy after 1 month of follow-up.
22. Joosten LAB, Helsen MMA, van de Loo FAJ, von den Berg WB: Anticytokine treatment of established type II collagen-induced arthritis in DA/1 mice. Arthritis Rheum 1996, 39:797-809. This paper demonstrates that in type Il CIA in DA/1 mice, TNF-α treatment primarily prevents synovitis, whereas IL-1 inhibition appears to be more effective in the prevention of cartilage destruction.
23. Lorenz HM, Antoni C, Valerius T, Repp R, Grünke M, Schwerdtner N, NüBlein H, Woody J, Kalden JR, Manger B: In vivo blockade of TNF-alpha by intravenous infusion of a chimeric monoclonal TNF-alpha antibody in patients with rheumatoid arthritis: short term cellular and molecular effects. J Immunol 1996, 156:1646-1653. Parallel to a clinical trial, cellular and molecular effects of a TNF-α therapy were analyzed in RA patients. The main effects were a reduction in monocyte counts and in monokines as well as a reduction in soluble ICAM-1 in the circulation.
24. Paleolog EM, Hunt M, Elliott MJ, Feldmann M, Maini RN, Woody JN: Deactivation of vascular endothelium by monoclonal anti-tumor necrosis factor alpha antibody in rheumatoid arthritis. Arthritis Rheum 1996, 39:1082-1091. In addition to reduced serum ICAM-1 levels under TNF-α therapy, as reported by Lorenz et al. (J Immunol 1996, 156:1646-1653), a decrease in serum E-selectin levels was found. No changes in levels of vascular cell adhesion molecule-1 were detected.
25. Tak PP, Taylor PC, Breedveld FC, Smeets TJM, Daha MR, Kluin PM, Meinders AE, Maini RN: Decrease in cellularity and expression of adhesion molecules by anti-tumor necrosis factor alpha monoclonal antibody treatment in patients with rheumatoid arthritis. Arthritis Rheum 1996, 39:1077-1081. In RA patients treated with anti-TNF-α antibody, significant reductions in T-cell infiltration and in expression of adhesion molecules were demonstrated in inflammatory synovial tissue.
26. Edwards III CK, Zhou T, Zhang J, Baker TJ, De M, Long RE, Borcherding DR, Bowlin TL, Bluethmann H, Mountz JD: Inhibition of superantigen-induced proinflammatory cytokine production and inflammation arthritis in MRL-lpr/lpr mice by a transcriptional inhibitor of TNF-alpha. J Immunol 1996, 157:1758-1772.
27. Kavanaugh AF, Cush JJ, St Clair EW, McCune WJ, Braakman TAJ, Nichols LA, Lipsky PE: Anti-TNF-alpha monoclonal antibody (mAB) treatment of rheumatoid arthritis (RA) patients with active disease on methotrexate (MTX): results of double-blind, placebo controlled multicenter trial [abstract]. Arthritis Rheum 1996, 39(suppl 9):123.
28. Baumgartner S, Moreland LW, Schiff MH, et al.: Double-blind, placebo-controlled trial of tumor necrosis factor receptor (p80) fusion protein (TNFR:Fc) in active rheumatoid arthritis [abstract]. Arthritis Rheum 1996, 39(suppl 9):74. A dose-dependent clinical response was reported in RA patients, which was in striking contrast to the placebo-treated group. No antibodies to the TNF-α receptor construct were detected.
29. Mori L, Iselin S, De Libero G, Lesslauer W: Attenuation of collagen-induced arthritis in 55-kDA TNF receptor type 1 (TNFR1)-IgG-treated and TNFR1-deficient mice. J Immunol 1996, 157:3178-3182. In mice deficient in TNF receptor type 1 and with a CIA-susceptible genetic background, it was demonstrated that the progression of arthritis and tissue destruction including ankylosis is dependent on TNF receptor type 1.
30. Campion GV, Lebsack ME, Lookabaugh J, Gordon G, Catalano M, the IL-1Ra Arthritis Study Group: Dose-range and dose-frequency of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis. Arthritis Rheum 1996, 39:1092-1101. As early as 2 weeks after the initiation of treatment with IL-1 receptor antagonist, clinical improvement was demonstrated by a decrease in tender joints, morning stiffness, and pain in patients with active RA.
31. Bresnihan B, Lookabaugh J, Witt K, Musikic P: Treatment with recombinant human interleukin-1 receptor antagonist (rhIL-1ra) in rheumatoid arthritis (RA): results of a randomized double-blind, placebo-controlled multicenter trial [abstract]. Arthritis Rheum 1996, 39(suppl 9):73.
32. Joosten LAB, Helsen MMA, van de Loo FAJ, van den Berg WB: Anticytokine treatment of established type II collagen-induced arthritis in DBA/1 mice: a comparative study using anti-TNF-alpha, anti-IL-1 alpha/beta, and IL-1RA. Arthritis Rheum 1996, 39:797-809. In CIA, anti-TNF-α treatment was efficacious when given shortly after onset of disease but had little effect on fully established disease, in contrast to IL-1-blocking therapies. This finding shows that blocking of TNF-α does not necessarily eliminate effects caused by IL-1.
33. Van Roon JAG, van Roy JLA, Gmelig-Meyling FHJ, Lafeber FPJG, Bijlsma JWJ: Prevention and reversal of cartilage degradation in rheumatoid arthritis by Interleukin-10 and Interleukin-4. Arthritis Rheum 1996, 39:829-835. As demonstrated in this study, IL-10 reverses the cartilage degradation induced by antigen-stimulated mononuclear cells. IL-4 has an additive effect on this process. These results provide evidence in favor of a combination of these two cytokines in the treatment of RA.
34. Sugiyama E, Taki H, Kuroda A, Mino T, Yamashita N, Kobayashi M: Interleukin-4 inhibits prostaglandin E2 production by freshly prepared adherent rheumatoid synovial cells via inhibition of biosynthesis and gene expression of cyclo-oxygenase II but not of cyclo-oxygenase I. Ann Rheum Dis 1996, 55:375-382.
35. Isomäki P, Luukkainen R, Toivanen P, Punnonen J: The presence of interleukin-13 in rheumatoid synovium and its antiinflammatory effects on synovial fluid macrophages from patients with rheumatoid arthritis. Arthritis Rheum 1996, 39:1693-1702. It is demonstrated that IL-13 is consistently present in rheumatoid synovium and that exogenously added IL-13 decreases the production of proinflammatory cytokines by synovial cells.
36. Bessis N, Boissier MC, Ferrara P, Blankenstein T, Fradeliji D, Fournier C: Attenuation of collagen-induced arthritis in mice by treatment with vector cells engineered to secrete interleukin-13. Eur J Immunol 1996, 26:2399-2403. These experiments demonstrated that the administration of IL-13 and IL-4 using vector cells engineered to secrete the proteins is a powerful method of attenuating significantly the progression of CIA. Other experiments have suggested that IL-13 exerts its beneficial effects by a down-regulation of expression of the TNF-α gene.
37. Sieper Kary S, Sörensen H, Aalten R, Eggens U, Hüge W, Hiepe F, Kühne A, Listing J, Ulbrich N, et al.: Oral type II collagen treatment in early rheumatoid arthritis: a double-blind, placebo-controlled, randomized trial. Arthritis Rheum 1996, 39:41-51.
38. Barnett ML, Combitchi D, Trentham DE: A pilot trial of oral type II collagen in the treatment of juvenile rheumatoid arthritis. Arthritis Rheum 1996, 39:623-628.
39. Nita I, Ghivizzani C, Galea-Lauri J, Bandara G, Georgescu HI, Robbins PD, Evans CH: Direct gene delivery to synovium: an evaluation of potential vectors in vitro and in vivo. Arthritis Rheum 1996, 39:820-828.
40. Early GS, Zhao W, Burns CM: Anti-CD40 ligand antibody treatment prevents the development of lupus-like nephritis in a subset of New Zealand black x New Zealand white mice: response correlates with the absence of an anti-antibody response. J Immunol 1996, 157:3159-3164. In a subset of NZB x NZW mice it was shown that an anti-CD40 ligand antibody prevented the development of lupus nephritis associated with a reduction of anti-DNA antibody titer and a significantly prolonged survival.